Loading
PRKD3 (Serine/threonine-protein kinase D3) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Leukaemia, Myeloproliferative neoplasms, Systemic mastocytosis and 1 more.
Converts transient diacylglycerol (DAG) signals into prolonged physiological effects, downstream of PKC. Involved in resistance to oxidative stress.
Open Targets scores its association with cancer at 0.59 (direct and indirect evidence; datatypes literature 0.96, animal model 0.42, genetic association 0.00, clinical 0.92).
In plain words · PRKD3 (Serine/threonine-protein kinase D3) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Leukaemia, Myeloproliferative neoplasms, Systemic mastocytosis and 1 more.
PRKD3 (Serine/threonine-protein kinase D3) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Leukaemia, Myeloproliferative neoplasms, Systemic mastocytosis and 1 more.
Converts transient diacylglycerol (DAG) signals into prolonged physiological effects, downstream of PKC. Involved in resistance to oxidative stress.
No product in this corpus aims at PRKD3 yet. Kinases are switched on by binding ATP inside the cell, so most drugs are small molecules shaped to plug that ATP pocket.
Broadly expressed or essential: HPA finds the RNA at low tissue specificity; a medicine acting on the wild-type protein would expose normal tissue too. HPA PRKD3: RNA low tissue specificity; no normal tissue stained high; highest cancer staining lymphoma (5 of 11 high). Distribution: 2 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Leukaemia, Myeloid neoplasms); Open Targets associates it with 1 specific cancer type at or above 0.5 (acute myeloid leukemia). (Rule 7 of scripts/fetch-target-specificity.ts.)
Sources: Human Protein Atlas PRKD3 tissue; Open Targets ENSG00000115825 associations
First described 1999. Earliest sequence paper UniProt cites for the protein: Hayashi et al, Biochim. Biophys. Acta, 1999, "PKCnu, a new member of the protein kinase C family, composes a fourth subfamily with PKCmu". Source.
Sources: HGNC HGNC:9408 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt O94806 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000115825 (association with cancer (MONDO_0004992) 0.59; per-cancer scores at or above 0.5: acute myeloid leukaemia 0.56, myeloproliferative neoplasm 0.56, systemic mastocytosis 0.54, leukaemia 0.57 (GraphQL API, CC0))
Converts transient diacylglycerol (DAG) signals into prolonged physiological effects, downstream of PKC. Involved in resistance to oxidative stress. Location: Cytoplasm; Membrane (UniProt). Locus 2p22.2 (HGNC).
RNA: low tissue specificity, detected in all normal tissues.
No normal tissue stained high.
Medium only: breast cancer, cervical cancer, colorectal cancer, glioma.
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"PRKD3" OR ABSTRACT:"PRKD3" OR TITLE:"protein kinase D3" OR ABSTRACT:"protein kinase D3" OR TITLE:"Serine/threonine-protein kinase D3" OR ABSTRACT:"Serine/threonine-protein kinase D3" OR TITLE:"PKD3" OR ABSTRACT:"PKD3" OR TITLE:"EPK2" OR ABSTRACT:"EPK2" OR TITLE:"PRKCN" OR ABSTRACT:"PRKCN") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about PRKD3, not a curated reading list.
Shares Systemic mastocytosis, Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Acute myeloid leukaemia.
Shares Systemic mastocytosis, Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Acute myeloid leukaemia.
Shares Systemic mastocytosis, Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Acute myeloid leukaemia.
Shares Systemic mastocytosis, Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Acute myeloid leukaemia.
Shares Systemic mastocytosis, Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Acute myeloid leukaemia.
Shares Systemic mastocytosis, Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Acute myeloid leukaemia.
Shares Systemic mastocytosis, Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Acute myeloid leukaemia.
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Acute myeloid leukaemia, Open Targets Platform.